Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
- Authors
- Hong, Young Joon; Jeong, Myung Ho; Bae, Jang Ho; Oh, Seok Kyu; Rha, Seung Woon; Hur, Seung Ho; Lee, Sung Yun; Kim, Sang Wook; Cha, Kwang Soo; Chae, In Ho; Ahn, Tae Hoon; Kim, Kee Sik
- Issue Date
- 7월-2017
- Publisher
- KOREAN ASSOC INTERNAL MEDICINE
- Keywords
- Myocardial infarction; Atherosclerosis; Lipids; Hydroxymethylglutaryl-CoA reductase inhibitors
- Citation
- KOREAN JOURNAL OF INTERNAL MEDICINE, v.32, no.4, pp.656 - 667
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- KOREAN JOURNAL OF INTERNAL MEDICINE
- Volume
- 32
- Number
- 4
- Start Page
- 656
- End Page
- 667
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/82997
- DOI
- 10.3904/kjim.2016.016
- ISSN
- 1226-3303
- Abstract
- Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy end-point was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 +/- 32.73 mg/dL vs. -34.23 +/- 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 +/- 54.49 mg/dL in 4 mg group and -24.45 +/- 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% +/- 1.21% in 4 mg group and -0.04% +/- 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.